Embecta (EMBC) to Release Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) will likely be announcing its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $256.08 million for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Tuesday, November 26th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.05. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. The company had revenue of $286.10 million during the quarter, compared to analyst estimates of $276.97 million. During the same period in the prior year, the firm earned $0.59 earnings per share. The business’s quarterly revenue was up 1.5% on a year-over-year basis. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Trading Down 3.1 %

EMBC stock opened at $18.40 on Thursday. Embecta has a one year low of $9.93 and a one year high of $21.48. The firm has a market capitalization of $1.07 billion, a PE ratio of 13.63, a P/E/G ratio of 1.02 and a beta of 1.23. The firm has a 50-day moving average of $19.52 and a two-hundred day moving average of $16.35.

Embecta Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th were paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date of this dividend was Friday, December 6th. Embecta’s dividend payout ratio is presently 44.44%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EMBC. Morgan Stanley raised shares of Embecta from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $13.00 to $20.00 in a research note on Monday, December 2nd. BTIG Research raised shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Wednesday, November 27th.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.